Pharmacological management of progressive-fibrosing interstitial lung diseases Book Section
| Authors: | Lazo, K.; Ibrahem, M. |
| Editor: | Esquinas, A. M. |
| Article/Chapter Title: | Pharmacological management of progressive-fibrosing interstitial lung diseases |
| Abstract: | In 2011, clinical practice guidelines were established by a joint assembly of representatives from the American Thoracic Society (ATS), the European Respiratory Society (ERS), the Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (LATA) to create recommendations for the treatment of Idiopathic Pulmonary Fibrosis (IPF). These guidelines were later updated in a 2015 statement published by the ATS [1]. These official joint statements, along with numerous other studies, continue to build upon current best practices to attenuate the progression of IPF. As of 2019, only two anti-fibrotic drugs have demonstrated clinical efficacy by significantly reducing decline in forced vital capacity - pirfenidone and nintedanib [2]. Current recommendations for the pharmacologic treatment of IPF are summarized in Table 1 [1, 2]. Other approaches to management seek to optimize patient's other comorbidities while providing symptom relief, pulmonary rehabilitation, and palliative care. In this chapter, we will discuss the pharmacologic therapies recommended for use in IPF, as well as discuss potential new therapies currently being investigated. © 2020 Nova Science Publishers, Inc. |
| Keywords: | pirfenidone; nintedanib |
| Book Title: | Respiratory Ventilatory Strategies in Acute and Chronic Respiratory Failure in Idiopathic Pulmonary Diseases: A Practical Approach |
| ISBN: | 9781536178470 |
| Publisher: | Nova Science Publishers, Inc |
| Publication Place: | New York, NY |
| Date Published: | 2020-07-01 |
| Start Page: | 303 |
| End Page: | 309 |
| Language: | English |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 31 -- Export Date: 3 January 2023 -- Source: Scopus |
MSK Authors
-
8Lazo
Related MSK Work